Skip to content
Sensei Biotherapeutics
Clinical-Stage Biotechnology
Sensei Biotherapeutics
  • About
  • Pipeline
    • Overview
    • SNS-101 (VISTA)
    • SNS-401-NG
    • SNS-VSIG4
    • Presentations
  • Platform
    • TMAb Platform
    • ImmunoPhage Platform
      • Therapeutic cocktails
      • Phortress
      • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • Sec Filings
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Shareholder Service
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us
Contact
  • About
  • Pipeline
    • Overview
    • SNS-101 (VISTA)
    • SNS-401-NG
    • SNS-VSIG4
    • Presentations
  • Platform
    • TMAb Platform
    • ImmunoPhage Platform
      • Therapeutic cocktails
      • Phortress
      • Immunophage + Nanobodies
    • GMP Manufacturing
    • Publications
  • Our Leadership
    • Senior Leadership
    • Board Of Directors
    • Immuno Oncology Advisory Board
  • Careers
  • Investors and Media
    • News Releases
    • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • Sec Filings
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Shareholder Service
      • Investor FAQs
      • Email Alerts
      • RSS Feeds
      • Contact Us

Daily Archives: December 12, 2020

SITC Safety and Efficacy

PresentationBy Sensei TeamDecember 12, 2020
…

Refractory Head and Neck Cancer Enrollment Update

PresentationBy Sensei TeamDecember 12, 2020
…

SITC TIP

PresentationBy Sensei TeamDecember 12, 2020
…

Iwagami Y et al. Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma. Heliyon. 2017, PMID: 28971150

PublicationBy Sensei TeamDecember 12, 2020
…

Arab A et al. Lambda phage nanoparticles displaying HER2-derived E75 peptide induce effective E75-CD8+ T response. Immunol Res. 2018, PMID: 29143917

PublicationBy Sensei TeamDecember 12, 2020
…

Razazan A et al. Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice. Sci Rep. 2019, PMID: 30778090

PublicationBy Sensei TeamDecember 12, 2020
…

Ghaemi A et al. Recombinant lambda-phage nanobioparticles for tumor therapy in mice models. Genet Vaccines Ther. 2010, PMID: 20459865

PublicationBy Sensei TeamDecember 12, 2020
…

Bartolacci C, et al. Phage-Based Anti-HER2 Vaccination Can Circumvent Immune Tolerance against Breast Cancer [published correction appears in Cancer Immunol Res. 2019, PMID: 30327365

PublicationBy Sensei TeamDecember 12, 2020
…

Burtness B, et al. KEYNOTE-048 Investigators. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019, PMID: 31679945

PublicationBy Sensei TeamDecember 12, 2020
…

Ferris RL et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016, PMID: 27718784

PublicationBy Sensei TeamDecember 12, 2020
…
12
© 2022 Sensei Biotherapeutics. All Rights Reserved.
  • Privacy Policy
Footer
Go to Top